Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance--HIV Drug Resistance in Sub-Saharan Africa and the Asia-Pacific

Jordan M, Bennett D, Bertagnolio S, Gilks C, Sutherland D . World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 2008; 13 Suppl 2:15-23. View

Rosen S, Fox M, Gill C . Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007; 4(10):e298. PMC: 2020494. DOI: 10.1371/journal.pmed.0040298. View

Rahim S, Fredrick L, da Silva B, Bernstein B, King M . Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials. 2009; 10(2):94-103. DOI: 10.1310/hct1002-94. View

Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R . TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods. 2009; 159(2):185-93. PMC: 2863146. DOI: 10.1016/j.jviromet.2009.03.016. View

Martinez-Cajas J, Pant-Pai N, Klein M, Wainberg M . Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 2008; 10(4):212-23. View

Bennett D, Bertagnolio S, Sutherland D, Gilks C . The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008; 13 Suppl 2:1-13. View

Dumans A, Soares M, Machado E, Hue S, Brindeiro R, Pillay D . Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis. 2004; 189(7):1232-8. DOI: 10.1086/382483. View

Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M . World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther. 2008; 13 Suppl 2:49-57. View

Braitstein P, Brinkhof M, Dabis F, Schechter M, Boulle A, Miotti P . Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006; 367(9513):817-24. DOI: 10.1016/S0140-6736(06)68337-2. View

10.

Kantor R, Katzenstein D, Efron B, Carvalho A, Wynhoven B, Cane P . Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005; 2(4):e112. PMC: 1087220. DOI: 10.1371/journal.pmed.0020112. View

11.

Rhee S, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R . Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003; 31(1):298-303. PMC: 165547. DOI: 10.1093/nar/gkg100. View

12.

McGowan C, Cahn P, Gotuzzo E, Padgett D, Pape J, Wolff M . Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol. 2007; 36(5):969-76. DOI: 10.1093/ije/dym073. View

13.

Wensing A, van de Vijver D, Angarano G, Asjo B, Balotta C, Boeri E . Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005; 192(6):958-66. DOI: 10.1086/432916. View

14.

Hemelaar J, Gouws E, Ghys P, Osmanov S . Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006; 20(16):W13-23. DOI: 10.1097/01.aids.0000247564.73009.bc. View

15.

Ivers L, Kendrick D, Doucette K . Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005; 41(2):217-24. DOI: 10.1086/431199. View

16.

Gupta R, Hill A, Sawyer A, Cozzi-Lepri A, von Wyl V, Yerly S . Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009; 9(7):409-17. DOI: 10.1016/S1473-3099(09)70136-7. View

17.

Jahn A, Floyd S, Crampin A, Mwaungulu F, Mvula H, Munthali F . Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet. 2008; 371(9624):1603-11. PMC: 2387197. DOI: 10.1016/S0140-6736(08)60693-5. View

18.

Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee C, Li P . The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr. 2005; 38(2):174-9. PMC: 3070962. DOI: 10.1097/01.qai.0000145351.96815.d5. View

19.

Hamers R, Siwale M, Wallis C, Labib M, van Hasselt R, Stevens W . HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010; 55(1):95-101. DOI: 10.1097/QAI.0b013e3181e544e0. View

20.

Hamers R, Derdelinckx I, van Vugt M, Stevens W, Wit T, Schuurman R . The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008; 13(5):625-39. View